Not all stem cell preparations are equal. Learn the key factors that determine the quality of mesenchymal stem cells used in research and therapy.
In mesenchymal stem cell (MSC) therapy, quality is everything. Two preparations may be labeled the same way yet differ significantly in their biological activity, purity, and safety profile.
Quality in MSC therapy is not a single number; it is a combination of several measurable characteristics. The International Society for Cell and Gene Therapy publishes minimal criteria that define what qualifies as an MSC. These criteria cover identity, behavior in culture, and the ability to differentiate into multiple lineages. On top of these baseline criteria, clinical-grade preparations follow additional safety and consistency standards. A quality-focused process treats every batch as a defined product, not a generic cell sample.
True MSCs express a defined set of surface markers, including CD73, CD90, and CD105. At the same time, they should be negative for markers such as CD45, CD34, CD14, and HLA-DR. This profile is typically confirmed using flow cytometry before cells are released. Without this verification, a sample cannot be reliably called an MSC preparation. Identity testing protects patients from receiving cells that do not match the expected biology.
Viability measures the percentage of living cells in the sample. Most clinical standards expect viability above 90% at the time of administration. Potency measures whether the cells can perform their expected functions, such as differentiation and signaling. Potency assays may include differentiation tests, immune modulation assays, or measurements of key secreted factors. Together, viability and potency describe both the quantity and the biological capability of the cells.
MSCs can be obtained from several human tissues, each with different characteristics. Umbilical cord sources tend to provide young cells with strong proliferative capacity. Bone marrow is the most studied source and has a long history in research. Adipose tissue is more accessible in adults and yields large numbers of cells. The right source depends on the application, the protocol, and donor screening practices.
Quality begins long before cells reach the patient. Donor screening for infectious disease and medical history is a foundational step. Cell processing should occur in GMP-compliant facilities with controlled environments. Culture media, oxygen levels, passage numbers, and handling steps are all defined in standard operating procedures. Documentation makes each batch traceable and reviewable, supporting both safety and continuous improvement.
Most MSC products are frozen in liquid nitrogen between manufacture and use. The cryopreservation media, freezing rate, and storage temperature all affect post-thaw viability. Thawing protocols must be standardized to avoid sudden temperature shifts that damage cells. Time between thaw and administration should be as short as is clinically practical. Proper handling at this stage protects the quality created during earlier processing steps.
Higher-quality cells are associated with more reliable outcomes in laboratory and clinical studies. They show stronger paracrine signaling and greater consistency between treatments. They also tend to have a better safety profile because they are well characterized. For patients, this means fewer unknowns and clearer expectations. For clinicians, it means treatments can be planned with greater confidence.
Patients considering MSC therapy can ask where the cells come from and how they are processed. A certificate of analysis covering identity, viability, sterility, and potency is a reasonable request. Information about the laboratory's accreditation and quality systems adds confidence. Clear answers about cell numbers, passages, and timing of administration are also important. Transparent providers are typically willing to share this information.
MSC quality is a combination of identity, viability, potency, and process control. Patients considering therapy benefit from asking how a clinic verifies the cells they use rather than relying on marketing claims.